Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$18.53 – $20.94
Volume44,484
Market cap$36M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$35.79M
Price / earnings
—
Price / book
2.41×
Price / sales
1.27×
EV / sales
1.18×
EV / EBITDA
-114.23×
Profitability
Earnings per share
-$0.64
Return on assets
-5.27%
Return on equity
-7.7%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.08×
Current ratio
1.77×
Quick ratio
1.54×
Cash ratio
0.9×
Cash flow
Price / cash flow
21.05×
Price / free cash flow
25.8×
Free cash flow
$1.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRPO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$7.39M
$7.02M
$6.96M
$6.82M
$6.89M
$5.63M
$4.91M
$5.31M
Cost of revenue
$4.01M
$3.89M
$4.24M
$3.69M
$3.88M
$3.2M
$2.77M
$2.67M
Gross profit
$3.38M
$3.14M
$2.73M
$3.13M
$3.01M
$2.43M
$2.14M
$2.65M
Selling, general and administrative
$0
$0
$0
$0
$0
$0
$0
$0
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$3.38M
$3.74M
$4.15M
$2.59M
$3.07M
$3.25M
$3M
$2.98M
Operating income
$2K
-$599K
-$1.43M
$542K
-$61K
-$824K
-$859K
-$336K
Interest expense
-$10K
$0
$0
$0
-$9K
$0
$0
$0
Income before taxes
-$8K
-$219K
-$1.44M
$526K
-$79K
$74K
-$884K
-$365K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8K
-$219K
-$1.44M
$526K
-$79K
$74K
-$884K
-$365K
Net income attributable to common shareholders
-$8K
-$219K
-$1.44M
$526K
-$79K
$74K
-$884K
-$365K
EBITDA
$314K
-$308K
-$1.15M
$849K
$246K
-$517K
-$535K
-$37K
Basic earnings per share
$0.00
-$0.12
-$0.81
$0.30
-$0.05
$0.05
-$0.59
-$0.24
Diluted earnings per share
$0.00
-$0.12
-$0.81
$0.31
-$0.05
$0.05
-$0.59
-$0.24
Recent news
Company coverage with links to the original publishers.
Precipio (PRPO) reported Q3 2026 revenues of $7.3 million, up 8.3% YoY, with near break-even results. The company is transitioning toward growth acceleration, targeting over $40 million in combined annualized revenue run rate by end of 2027. Despite improved liquidity and gross margins, management expressed substantial doubt about going concern status. PRPO plans to double its sales force and leverage distribution partnerships with major healthcare companies.
Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will host its Q3-2026 shareholder update call on November 10th, 2026. CEO Ilan Danieli highlighted continued revenue growth with the Products Division reaching an important milestone. The call will include company remarks and a moderated live Q&A session, with management providing insights into performance, strategy, and 2027 outlook.
Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.
Precipio Inc. (NASDAQ: PRPO) is urging shareholders to vote immediately to reach the 50% quorum requirement for its Annual Shareholders Meeting scheduled for June 15, 2026. As of the press release date, only 42% of shares had been voted. The company is seeking to avoid costly adjournment and rescheduling expenses if sufficient votes are not received by the June 14 deadline.
Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026. CEO Ilan Danieli and COO Zaki Sabet will host the presentation. The company emphasized it is profitable and focused on raising awareness and building its shareholder base rather than raising capital.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.